Gland Pharma Ltd. for Q1FY23 reports a 35% fall in Profits

Revenue has fell by 26% YoY to ₹8,569 millions. Core Market Revenue has decreased by 6% and Rest of the world revenue fell by 55% YoY. Profit fell by 35% YoY to ₹2,292 millions for Q1FY2023. Total Expenses fell by 16% and Cash Flow from Operating Activities increased by 84% to ₹3,329 millions.

ROCE fell to 12% and EBITDA margin fell to 37%. Profit Before Tax (PBT) fell by 35% YoY to ₹3,085 millions. The management has shared that supply disruptions and rising input costs are the reasons for the decreased profits in this quarter. In this quarter’s press release, management suggested their focus is sustainable growth through investing in their own resouces and people.

To further compare this quarter’s results to the past, check out this link.